- Bavarian Nordic received Health Canada approval for Vimkunya, a single-dose vaccine to prevent chikungunya virus infection in individuals aged 12 years and older.
- Vimkunya is the first virus-like particle (VLP) chikungunya vaccine approved in Canada, expanding preventive options for travelers to endemic and outbreak regions.
- The approval marks Vimkunya’s fifth global authorization, following approvals from the US FDA, European Commission, UK MHRA, and Swissmedic.
- The recombinant, adjuvanted vaccine is non-infectious, contains no viral genetic material, and is designed to provide protective immunity as early as one week after vaccination.
Takeaways:
Vimkunya’s Health Canada approval turns Bavarian Nordic’s chikungunya shot into a genuinely global travel-vaccine franchise, which should drive uptake in Canadian travel clinics and specialty pharmacies and strengthen its positioning with multinational procurement bodies now that North America and key European regulators are aligned. The single-dose, rapid-onset, non-infectious VLP profile fits real-world traveler behavior and may make Vimkunya the default choice for Canadians going to endemic or outbreak regions, increasing commercial momentum and raising the bar for any future competitors in the chikungunya prevention space.
Source: Bavarian Nordic
